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Introduction
The PCTAIRE family is a branch of kinases related to the 
Cdk family that includes PCTAIRE1 (also known as PCTK1 
and Cyclin-dependent kinase 16 (Cdk16)), PCTAIRE2 and 
PCTAIRE3.1 PCTAIRE1 is broadly expressed throughout 
the body, with highest levels seen in the brain and testes.2 
PCTAIRE1 has a central kinase domain that shows amino 
acid sequence similarity to those of Cdk proteins, and 
this region is flanked by unique N-terminal and C-terminal 
domains.1 The mechanisms responsible for PCTAIRE1 
activation are unknown, but the finding that deletion of the 
N-terminal domain abolishes kinase activity in vitro sug-
gests that this region is important and that it may bind an 
unknown cofactor or interact intramolecularly with the central 
kinase domain to promote active conformations of the cata-
lytic domain.3 We recently discovered that PCTAIRE1 plays 
an indispensable role in cancer cell proliferation,4–6 as well 
as in antiapoptosis.7 We showed that PCTAIRE1-knockdown 
cancer cells promote late G2-mitotic arrest associated with 
defects in centrosome dynamics.4 Furthermore, PCTAIRE1 
phosphorylates p27 at Ser10, which facilitates p27 degra-
dation. PCTAIRE1 is overexpressed by a large number of 
human tumors, including colon, breast, prostate, and brain 
cancers, and also malignant melanomas.8 Thus, PCTAIRE1 
is an attractive target for therapeutic interventions.
Small interfering RNA (siRNA) technology is an intrigu-
ing and powerful method of gene down-regulation that has 
been widely used to study gene function and to target drugs 
for discovery.9,10 Recently, several studies have found highly 
efficient methods for the in vivo delivery of siRNA, especially 
by lipid nanoparticles (LNP) technologies.11,12
Based on the known functions of PCTAIRE1 and the prom-
ising in vitro results of PCTAIRE1 silencing, we investigated 
the in vivo antitumor effects of PCTAIRE1 silencing using 
siRNA incorporated in LNP.
Results
Knockdown of PCTAIRE1 regulates HCT116 colorectal 
cancer cell growth and proliferation in vitro
To investigate the effect of PCTAIRE1 knockdown in colorec-
tal cancer HCT116 cells, we performed siRNA experiments 
using two siRNAs that were previously shown to effectively 
target PCTAIRE1.4,5 In vitro siRNA experiments were per-
formed with Lipofectoamine RNAiMax transfection reagent, 
since lipid-enabled and unlocked nucleic acid- modified RNA 
(LUNAR) lipid delivery technology platform was unsuitable for 
in vitro use. Immunoblotting confirmed knockdown of protein 
levels by both of the PCTAIRE1-targeting siRNAs (see Sup-
plementary Figure S1a). Next, human HCT116 colorectal 
cancer cells were treated with siRNAs targeting PCTAIRE1 
versus negative control RNAs, and cell viability was assessed 
3 days later. Cultures of PCTAIRE1 knockdown HCT116 cells 
showed reduced numbers of viable cells compared with con-
trol transfected cell cultures using ATP levels (see Supple-
mentary Figure S1b). Similar results were obtained by direct 
cell-counting methods, showing a reduction in the numbers 
of viable cells in cultures of HCT116 cells within 3 days after 
PCTAIRE1 siRNA treatment (see Supplementary Figure 
S1c). Based on previous studies,4,8 the expression levels of 
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PCTAIRE1/CDK16/PCTK1 plays critical roles in cancer cell proliferation and antiapoptosis. To advance our previously published 
in vitro results with PCTAIRE1 silencing, we examined the in vivo therapeutic potential of this approach by using small 
interfering RNA (siRNA) encapsulated by lipid nanoparticles. Therapy experiments of PCTAIRE1 siRNA were performed using 
human HCT116 colorectal cancer cells and human A2058 melanoma cells. A single dose of PCTAIRE1 siRNA-lipid nanoparticles 
was found to be highly effective in reducing in vivo PCTAIRE1 expression for up to 4 days as assayed by immunoblotting. 
Therapy experiments were started 4 days after subcutaneous injection of cancer cells. Treatment with PCTAIRE1 siRNA-lipid 
nanoparticles (0.5 mg/kg RNA, twice a week) reduced tumor volume and weight significantly compared with the scramble-
control group. Histopathological analysis (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) showed 
increased apoptosis of tumor cells treated with PCTAIRE1-siRNA. Overall, our results demonstrate that siRNA treatment 
targeting PCTAIRE1 is effective in vivo, suggesting that PCTAIRE1 siRNA-lipid nanoparticles might be a novel therapeutic 
approach against cancer cells.
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c-Myc and tumor suppressor p27 were assessed by immu-
noblotting, showing that knockdown of PCTAIRE1 leads to 
the accumulation of p27 and down-regulation of c-Myc (see 
Supplementary Figure S1a).
Delivery of siRNA into xenograft tumor
In this study, LNP-siRNA (size: 40–50 nm) with modification 
of cationic lipids and polyethylene glycol (PEG) density were 
used as the delivery vehicle to target xenograft tumors. To 
examine whether siRNA could be effectively delivered into 
tumor cells, we used a nonsilencing siRNA tagged with the 
fluorochrome Cy5 in LNP complexes (LUNAR lipid delivery 
platform). Nude mice with HCT116 xenograft tumors at 15 
days after subcutaneous inoculation of tumor cells were 
intratumorally or i.v. injected with 10 µg LNP-conjugated non-
silencing siRNA/Cy5 (0.5 mg/kg). After 6 hours, tumors and 
major organs were harvested and examined for fluorescence 
using Xenogen IVIS 200 imaging system imaging. Cy5 signal 
was detected in tumors but not in major vital organs, sug-
gesting that LNP-RNA was distributed mainly in the xenograft 
tumors (Figure 1a, b).
In vivo down-regulation of PCTAIRE1 by LNP-siRNA
Before initiating therapy experiments, we examined the ability 
of PCTAIRE1-targeted siRNA incorporated in LNP to down-
regulate PCTAIRE1 in vivo. Nude mice bearing subcutaneous 
HCT116 xenograft tumors were injected with a single dose 
of PCTAIRE1 siRNA (#2)-LNP or scramble-control (0.50 mg/
kg), and tumors were harvested 1, 2, 3, 4, and 7 days after 
injection for immunoblot analysis to assess the level of 
PCTAIRE1 expression. The immunoblot analysis revealed 
a >70% reduction in PCTAIRE1 levels within 2 days, which 
persisted for at least 4 days (Figure 2). PCTAIRE1 expres-
sion began to return to basal levels by 7 days after a single 
treatment. In tumors treated with scramble-control RNA or 
untreated tumors, the expression levels of PCTAIRE1 were 
not reduced (see Supplementary Figure S2). Therefore, we 
selected twice-weekly administration of siRNA-LNP as the 
optimal dosing schedule for subsequent therapy experiments.
In vivo tumor growth was inhibited by LNP-mediated 
siRNA-transfer against PCTAIRE1
To assess effects from the delivery vehicle, we compared the 
untreated and LNP-scramble treated tumors. We generated 
HCT116 cell xenografts by injecting the cells (5 × 106 cells) sub-
cutaneously into nu/nu mice. At day 4, LNP-siRNA intratumoral 
injections (scramble control RNA, 0.50 mg/kg) were started and 
were repeated four times (twice weekly). The extracted tumor 
weights were assessed at day 16, showing that vehicle was not 
harmful to HCT116 xenograft tumor growth (see Supplemen-
tary Figure S3). Next, in order to determine the effect of LNP-
siRNA against PCTAIRE1 on HCT116 tumor growth in vivo, 
LNP-siRNA intratumoral injections (0.50 mg/kg) were started 
at day 4 after the cell injections and were repeated four times 
(twice weekly) as performed above (Figure 3a). We continued 
to measure the tumor volume in each animal every 3 days dur-
ing the procedure and found that tumor growth was significantly 
inhibited in the group treated with siRNA targeting PCTAIRE1 
compared with the scramble-control groups. In contrast to the 
large tumors produced by the control groups, the mice treated 
with siRNA against PCTAIRE1 produced small tumors (Figure 
3c,d,e). Similar results were obtained in A2058 melanoma cells 
(see Supplementary Figure S4). Total protein lysates were 
isolated from the tumors of the two groups. The PCTAIRE1 
protein was almost undetectable in the siRNA-treated samples 
(Figure 3b), suggesting that the inhibition of tumor growth in the 
siRNA-treated group was a consequence of PCTAIRE1 deple-
tion in the tumors. Immunohistochemical analysis also showed 
increased expression of apoptotic markers (TUNEL assay) 
Figure 1  In vivo LNP-RNA distribution to tumors and major organs. HCT116 cells were inoculated to both flanks of nu/nu mice. At 2 
weeks, siRNAs conjugated with Cy5 (Cy5-siRNAs: 10 µg) were injected into the mice i.v. or were injected directly into the tumor using LUNAR 
lipid delivery technology platform. In the intratumoral injection, Cy5-siRNAs were injected into the tumor on one side of the body (red arrow), 
but not into the tumor on the other side of the body (black arrow). Cy5 signals were photographed by IVIS200, 6 hours after intratumoral or i.v. 











Figure 2 In vivo down-regulation of PCTAIRE1 by PCTAIRE1 
siRNA. Immunoblot of lysates from tumor samples collected 0, 
1, 2, 3, 4, and 7 days after a single administration of PCTAIRE1 
siRNA (10 µg, 0.5 mg/kg) incorporated in lipid nanoparticles (LUNAR 
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in resected PCTAIRE1 knockdown tumor xenografts (Figure 
4a-e). These results indicated that siRNA targeting PCTAIRE1 
elicited a strong antitumor effect on colorectal cancer in vivo.
Discussion
In this study, we report that PCTAIRE1 down-regulation can 
suppress in vivo xenograft tumor growth, which also strongly 
suggests that this is a promising novel therapeutic approach 
for cancer cells. We have proposed that PCTAIRE1 may be a 
therapeutic target for various cancers, especially for malignant 
lesions where aberrant upregulation of this kinase has been 
detected.4–6 The suppression of growth and increased apop-
tosis were the most common consequences of PCTAIRE1 
knockdown mediated by RNA interference (RNAi) in tumor 
cells. Interestingly, a recent study reported PCTAIRE1 silenc-
ing to be effective in inhibiting in vitro growth of medulloblas-
tomas.8 Furthermore, we and another group have shown that 
PCTAIRE1 regulates cell division.13 Collectively, the above 
observations strongly suggest that cancer treatments target-
ing PCTAIRE1 may be effective against aggressive tumors in 
which a number of cell divisions take place. Several effects 
of PCTAIRE1 downregulation, such as the accumulation of 
tumor suppressor p27 and the down-regulation of c-Myc,8 
have been observed previously in cancer cells. These phe-
nomena may account for the observed growth suppression or 
apoptosis of HCT116 and A2058 xenograft tumors. Because 
of the pivotal role of PCTAIRE1 in many processes associ-
ated with cancer progression, interfering with its function 
may represent novel therapeutic opportunities. Various strat-
egies for targeting PCTAIRE1 have been proposed and small 
molecule inhibitors that act as competitors for adenosine 
triphosphate (ATP) binding at the catalytic site are being 
developed.8 RNAi is a potent and powerful strategy for regu-
lating gene expression, and we and others using siRNA for 
down-regulating PCTAIRE1 in vitro along with the in vivo data 
presented in this article highlight its promise for clinical use.
RNAi delivery is crucial to realizing the potential of RNAi 
effects, and LNP have been shown to be highly effective in the 
delivery of siRNAs to the liver.12,14 For clinical use of siRNA, 
Coelho et al. reported the safety and efficacy of RNAi for tar-
geting transthyretin amyloidosis, showing that in vivo siRNA 
therapy is effective in humans.15 Thus, liver-tissue targeted 
LNP-mediated siRNA therapy is promising for clinical devel-
opment. Alternative approaches for knockdown in tumors 
or other organs have also been investigated.16 Specifically, 
the targeting of tumors could be enabled through the modu-
lation of LNP (particle sizes or addition of targeting ligands). 
Targeted receptors for siRNA delivery to tumors include Her2, 
EGFR, EpCAM, and folate receptors.16 Reportedly, LNP con-
sisting of antigen or antibody showed successful gene silencing 
in vitro. Furthermore, Kumar et al. reported the rational design 
of LNP-based siRNA delivery systems with an optimal safety 
and efficacy profile.17 To date, in vivo tumor-targeted siRNA 
delivery systems have not yet been well established; however, 
molecules conjugated to LNP could be developed for tumor-tar-
geted systemic siRNA therapy (i.v. or orally) in the near future.
In summary, we have shown that PCTAIRE1 siRNA deliv-
ered using a lipid nanoparticle system is highly effective 
for down-regulating PCTAIRE1 expression in vivo. Further-
more, treatment with PCTAIRE1 siRNA was found to be 
effective in inhibiting cancer cell growth. These findings 
suggest that PCTAIRE1 siRNA could be a potent therapy 
in patients with tumors overexpressing PCTAIRE1. Our 
Figure 3 In vivo therapeutic efficacy of siRNA-mediated PCTAIRE1 knockdown in HCT116 cells. (a) Experimental design. HCT116 cells 
(5.0 × 106 cells resuspended in 200 µl phosphate-buffered saline (PBS)) were subcutaneously injected into the flanks of 7-week-old female 
nu/nu mice. When tumor volumes reached 10–30 mm3 (Day 4), small interfering RNAs (siRNAs) targeting PCTAIRE1 or scramble-control with 
lipid nanoparticles (at a dose of 10 µg siRNAs, 0.5 mg/kg) were injected into tumors twice a week (n = 10 mice per group) using LUNAR lipid 
delivery technology platform. All animals were sacrificed at Day 16 after four siRNA treatments.(b) Immunoblot of lysate from xenograft tumors 
collected after administration of control siRNA (n = 4) or PCTAIRE1-targeting (n = 4) siRNA. (c) All the extracted tumors were photographed. 
(d) Tumor volumes (mm3) were measured every 3 days. *** P < 0.001 by t-test. (e) Tumors recovered from sacrificed mice were weighed 
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previous study shows that PCTAIRE1 knockdown sensi-
tizes cancer cells to tumor necrosis factor -family cytokines, 
including tumor necrosis factor -related apoptosis- inducing 
ligand.7 Thus, LNP-mediated in vivo PCTAIRE1 gene 
knockdown may have synergistic effects with tumor necro-
sis factor -family cytokines.
Materials and methods
Cell lines and cell culture. The human HCT116 colorectal 
cancer cell lines and human A2058 melanoma cells were 
purchased from the American Type Culture Collection. Cell 
lines were cultured in Dulbecco’s modified essential medium 
supplemented with 10% fetal bovine serum. All cells were 
used within 6 months of continuous passage.
Preparation of siRNA nanoparticles. Using the proprietary 
LUNAR™ lipid delivery technology platform, Arcturus Thera-
peutics (San Diego, CA) created test articles containing 
PCTAIRE1 siRNA (sense: 5′-rG*rGrCrArArArArGrCrArArGrC
rUrCrArCrArGdT*dT-3′; antisense: 3′-rC*rUrGrUrGrArGrCrUr
UrGrCrUrUrUrUrGrCrCdT*dT-5′, wherein rN is RNA, dT is 2′-
deoxy T, and * is phosphorothioate), nonsilencing control siRNA 
(sense: 5′-rC*rArArCrArArGrArUrGrArArGrArGrCrArCrCrArA*
dT*dT-3′, antisense: 3′-rUrUrG*rGrUrGrCrUrCrUrUrCrArUrCrU
rUrGrUrUrGdT*dT-5′, wherein rN is RNA, dT is 2′-deoxy T, and 
* is phosphorothioate, the sequence is identical to PCTAIRE1-
siRNA-2 from Life technologies), which was synthesized by 
Avetra Bioscience (Mountain View, CA). The LNPs were pre-
pared by mixing appropriate volumes of lipids in ethanol with 
an aqueous phase containing siRNA duplexes, employing a 
Nanoessembler™ microfluidic device, followed by downstream 
processing. For the encapsulation of siRNA, the desired amount 
of RNA was dissolved in 5 mmol/l citric acid buffer of pH 3.5. 
Lipids at the desired molar ratio were dissolved in ethanol. The 
mol% ratio for the constituent lipids is 58% ATX (proprietary 
ionizable amino lipids), 7% DSPC (1,2-dioctadecanoyl-sn-
glycero-3-phosphocholine) (Avanti Polar Lipids, Alabaster, AL), 
33.5% cholesterol (Avanti Polar Lipids), and 1.5% DMG-PEG 
(1,2-Dimyristoyl-sn-glycerol, methoxypolyethylene glycol, PEG 
chain molecular weight: 2000) (NOF America Corporation, 
White Plains, NY).17–20 At a flow ratio of 1:3 ethanol:aqueous 
phases, the solutions were combined in the microfluidic device 
(Precision Nano Systems, Vancouver, Canada) using two 
HPLC prep pumps (AZURA P 2.1L, Knauer, Berlin, Germany). 
The total combined flow rate was 12 ml/min per microfluidics 
chip. Anywhere from 1 to 4 microfluidics chips were utilized, in a 
custom unit for parallelization (Precision Nano Systems), allow-
ing a variable throughput for different batch sizes. The micro-
fluidics chips employ a herringbone micromixer for extremely 
quick mixing times, yielding high encapsulation and narrow 
particle size distribution.21,22 The mixed material was then 
diluted 3× with deionized water after leaving the micromixer 
outlet, reducing the ethanol content to 6.25%. The diluted LNP 
slurry was concentrated on a tangential flow filtration (TFF) with 
hollow fiber membranes (mPES Kros membranes, Spectrum 
Laboratories, Rancho Dominguez, CA), and then diafiltration 
was performed with modified Dulbecco's phosphate-buffered 
saline, without magnesium or calcium (HyClone, Logan, UT). 
A total of 10 diavolumes were exchanged, effectively remov-
ing the ethanol. Particle size was determined by dynamic light 
scattering (ZEN3600, Malvern Instruments, UK). Encapsula-
tion efficiency was calculated by determining unencapsulated 
siRNA content by measuring the fluorescence upon the addi-
tion of RiboGreen (Molecular Probes, Eugene, OR) to the LNP 
slurry (Fi) and comparing this value to the total siRNA content 
obtained upon lysis of the LNPs by 1% Triton X-100 (Ft), where 
% encapsulation = (Ft − Fi)/Ft × 100.
RNAi in vitro. For transient knockdown, cells were transfected 
with siRNA duplexes by a reverse transfection method using 
Lipofectoamine RNAiMAX according to the manufacturer’s 
instructions (Life Technologies, Carlsbad, CA).
Reagents and antibodies. Predesigned siRNA directed against 
human PCTAIRE1 (siRNA#1:1472, siRNA#2:1656) and nega-
tive scramble control (#1) were purchased from Life Tech-
nologies. Antibodies against PCTAIRE1 (rabbit: HPA001366, 
Sigma, St. Louis, MO), beta-actin (Sigma) and horseradish per-
oxidase (HRP)-conjugated secondary antibodies (GE Health 
Care, Chicago, IL) were purchased from the indicated sources.
Figure 4 Gene knockdown of PCTAIRE1 leads to apoptosis of xenograft tumors. (a–d) Representative images of hematoxylin-eosin 
stain (a, c) and immunohistochemistry with TUNEL stain (b, d). (Inset: low magnification; Scale bar = 100 µm). (e) The number of apoptotic 
cells (brown) were counted (Columns, mean percentage of TUNEL-positive cells, n = 12, determinations based on examination of 100 tumor 
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SDS-PAGE and immunoblotting. Cells were washed twice with 
phosphate-buffered saline (PBS) and harvested with radioim-
munoprecipitation assay (RIPA) buffer composed of 20 mmol/l 
Tris-HCl (pH 7.5), 150 mmol/l NaCl, 0.1 mmol/l ethylenedi-
aminetetraacetate (EDTA), 1% Nonidet P-40, 0.1% SDS, 5 
mmol/l NaF and an EDTA-free complete protease cocktail 
tablet (Roche, Basel, Switzerland). Cells were left on ice for 
20 minutes before being centrifuged at 14,000g for 10 min-
utes. The Bio-Rad protein assay kit (Bio-Rad, Hercules, 
CA) was used to determine protein concentrations. Pro-
teins were separated on sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), 4–15% gradient 
gels (Life Technologies) and transferred onto nitrocellulose 
membranes (Bio-Rad). Membranes were blocked for 1 hour 
in Tris-buffered saline with 0.05% Tween-20 and 5% nonfat 
dry milk, and then incubated overnight at 4°C with primary 
antibodies diluted in blocking buffer. Membranes were rinsed 
three times in Tris-buffered saline with 0.05% Tween-20 and 
incubated with secondary HRP-conjugated antibodies for 1 
hour at room temperature. An enhanced chemiluminescence 
method (GE Health Care) was used for detection.
In vivo imaging. After the injection of Cy5-conjugated siRNA, 
the mice were anesthetized and placed on the imaging 
stage of the IVIS apparatus in the abdominal (subcutaneous 
model) position. Images were collected from 1 to 20 min-
utes using the IVIS Imaging System (Xenogen, PerkinElmer, 
Waltham, MA). The Cy5 fluorescent signal was detected at a 
615–665 nm excitation wavelength and a 695–770 nm emis-
sion wavelength using the IVIS 200.
Cell viability assays using ATP measurement. Cell Titer Glo 
(Promega, Fitchburg, WI) was used for cell viability estima-
tion. Cells were plated at a density of 5,000 cells per well in 
100 µl and cultured for 72 hours with or without treatment. The 
plates were then removed from the incubator and allowed to 
equilibrate to room temperature for ~10 minutes. Cell Titer 
Glo solution was added at 100 µl per well, and the plates 
were kept in the dark for 15 minutes before being assessed 
for luminescence with a luminometer (Luminoskan Ascent; 
Thermo Scientific) at a 1 second integration time per sample.
Cell growth assay. To measure cell growth rates, 2.0 × 105 cells 
were reverse-transfected with siRNAs targeting PCTAIRE1 
or the scramble control using Lipofectoamin RNAiMax. After 
3 days, the numbers of cells were counted.
Tumor xenograft experiments. All animal experiments were 
approved by the IACUC of the Sanford-Burnham-Prebys Med-
ical Discovery Institute. Cancer cells (5.0 × 106) resuspended 
in 200 µl PBS were injected subcutaneously into the flanks 
of nu/nu mice. Tumor size was measured every 3 days in two 
dimensions using calipers and tumor volume was calculated 
using the following formula: (long axis × short axis2)/2. The 
endpoint was set at when tumors grow >1000 mm3 (Day16 in 
HCT116 xenograft and Day 21 in A2058 xenograft).
Immunohistochemistry. The detection of nuclei with frag-
mented DNA by terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) assay was 
accomplished using the ApopTag Peroxidase In situ Apopto-
sis Detection Kit (Chemicon, Temecula, CA) according to the 
manufacturer’s instructions. To quantify TUNEL-positive cells, 
the number of brown-positive cells was counted in 12 random 
fields at ×200 magnification.
Statistical analysis. Means and standard deviation (SD) were 
calculated statistically from three determinations. The data 
are expressed as mean ± SD. The statistical significance of 
differences between various samples was determined by 
Student’s t-test. P < 0.05 was considered significant.
Supplementary material
Figure S1. Knockdown of PCTAIRE1 diminishes HCT116 
cell growth in vitro.
Figure S2. Scramble RNA does not affect the expression 
levels of PCTAIRE1 in vivo.
Figure S3. LUNAR lipid delivery platform is not harmful to 
xenograft tumors in vivo.
Figure S4. In vivo therapeutic efficacy of siRNA-mediated 
PCTAIRE1 knockdown in A2058 cells.
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